New Melanoma Vaccine Could Cut Recurrence Risk by 42%
A new trial shows an mRNA vaccine plus immunotherapy may help adults stay cancer-free after surgical tumor removal.
Updated on Oct. 22, 2026 in Cancer
Live Poll
Do you trust personalized mRNA vaccines to effectively reduce cancer recurrence in patients?
A combination of an experimental mRNA vaccine and pembrolizumab reduced the risk of melanoma recurrence or death by 42 percent in a recent trial. These interim findings suggest the personalized approach may help improve outcomes for patients following surgery for melanoma.
Why it matters
For patients who have undergone surgery for melanoma, this combination therapy offers a potential new strategy to prevent cancer from returning. By tailoring treatment to an individual's specific tumor profile, this approach aims to boost the immune system's ability to clear remaining cancer cells.
In a Phase 3 trial of 1,137 participants who underwent surgery for melanoma, researchers found that the combination of a personalized mRNA vaccine and pembrolizumab reduced the risk of recurrence or death by 42 percent compared to pembrolizumab alone. These results are interim findings.
The players
Moderna
A pharmaceutical company known for developing mRNA-based vaccine technologies and therapies.
European Society for Medical Oncology
A professional organization that provides a forum for oncology research, clinical practice, and education.
Professor Georgina Long
An oncology researcher who presented the findings while based in Lisbon, Portugal.
The details
The treatment works by sequencing the genome of a patient's tumor and comparing it with their healthy cells to identify unique neoantigens. These markers are used to create a tailor-made vaccine that trains the immune system to recognize and destroy distinct cancer cells. Combined with pembrolizumab, which helps the immune system better identify tumors, the therapy targets potential remaining cancer cells following surgery.
Timeline
August 2026 saw a 170 percent surge in Moderna share prices.
October 18, 2026, marks the date trial results were leaked by an oncology website.
October 20, 2026, was when the interim analysis was presented at the European Society for Medical Oncology.
Health Landscape
This development represents a major step forward in the ongoing research into personalized neoantigen mRNA cancer vaccines. It moves the field closer to standardizing individual tumor-profiling treatments, which historically have been limited to smaller pilot studies.
Patients who have had surgery for melanoma should discuss the emergence of neoantigen-based therapies with their oncology care team to determine if such approaches may be relevant to their long-term management. As these treatments continue to be studied, maintaining regular surveillance for recurrence remains a critical part of post-surgical care.
The takeaway
This trial underscores the growing role of personalized immunology in treating post-surgical melanoma. Discussing the current standard of follow-up care and monitoring schedules with your oncologist is the best way to stay informed about available preventive strategies.
Further reading
For more information on the evolving landscape of melanoma treatments, visit our Cancer section.
Live Poll
Do you trust personalized mRNA vaccines to effectively reduce cancer recurrence in patients?
